Table 1.

Characteristics of study patients according to the presence or absence of AGS symptoms with potential sources of alpha-gal and their sex

	Group 1 (n = 33)	Group 2 (n = 65)
Sociodemographic Data
Sex, n(%)
Women  Men	3 (9.1) 30 (90.9)	40 (65.5) 25 (38.5)
Age (years), mean (SD)  Women  Men	46.91 (13.24) 36.33 (6.60) 47.97 (13.27)	47.65 (14.84) 45.23 (14.36) 51.52 (14.77)
Tick bites, n (%)  Women  Men	27 (81.8) 2 (66.7) 25 (83.3)	18 (27.7) 11 (27.5) 7 (28.0)
Outdoor activities, n (%)  Women  Men	33 (100.0) 30 (100.0) 3 (100.0)	49 (75.4) 28 (70.0) 21 (84.0)
Clinical Features
Symptoms with potential sources of alpha-gal, n (%)  Women  Men	33 (100.0) 3 (9.1) 30 (90.9)	0 (0.0) 0 (0.0) 0 (0.0)
Tolerance to potential sources of alpha-gal, n (%)  Women  Men	0 (0.0) 0 (0.0) 0 (0.0)	65 (100.0) 40 (65.5) 25 (38.5)
Immunological Data
Total IgE (kUA/L), mean (SD)  Women  Men	495.99 (747.65) 308.73 (363.37) 514.72 (773.18)	334.10 (601.85) 244.54 (474.37) 477.39 (740.53)
sIgE to alpha-gal (kUA/L), mean (SD)  Women  Men	31.70 (36.06) 0.81(0.35) 9.29 (44.45)	0.28 (1.41) 0.03 (0.12) 0.67 (2.21)
sIgE to alpha-gal ≥ 0.1 kUA/L, n (%)  Women  Men	32 (98.0) 2 (6.1) 30 (90.9)	7 (10.8) 2 (3.1) 5 (7.7)
sIgE to alpha-gal ≥ 2.0 kUA/L, n (%)  Women  Men	26 (78.79) 0 (0.0) 26 (86.67)	2 (3.08) 0 (0.0) 2 (8.00)

Group 1: Patients with AGS symptoms after being exposed to potential sources of alpha-gal

Group 2: Patients without AGS symptoms after being exposed to potential sources of alpha-gal

AGS, Alpha-gal Syndrome; kUA/L, kilounits or antibody per liter; sIgE, specific IgE